focus -WSS

focus

author：knowledge 2025-10-02 20:48:26 - browse：67587

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Heart attack and stroke risk calculators need revising

WSS

Activists slam private health insurers over coverage restrictions

In Memoriam: Notable people who died in 2023

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Congress: Eradicate hepatitis C and reduce the deficit

Grail faces three suits alleging harassment, retaliation

Tori Bowie and the unacceptable rates of Black maternal death

hotspot

focus

explore

Virginia high school admissions case could be legal follow

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Apple is now the first public company to be valued at $3 trillion

Activists slam private health insurers over coverage restrictions

The high cost of giving birth even with insurance

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medical records are filled with copy

Peter Hotez and the public health issue of online harassment

Novavax promises a turnaround & Lilly roils the obesity market

Congress: Eradicate hepatitis C and reduce the deficit

hotspot

J&J expands global access to TB drug amid advocacy campaign

Argenx drug significantly slows progression of nerve disorder

Who gets to use the title 'doctor'?

ChatGPT in medicine: STAT answers readers' burning questions

Virginia high school admissions case could be legal follow

Can CDC director Mandy Cohen drive consensus in Washington?

hotspot

hotspot

Wikipedia

focus